Amylin pharmaceuticals, the manufacturer of exenatide, offers the following reply

New England Journal of Medicine

Volumn 358, Issue 18, 2008, Pages 1971-1972

  Bloomgren, Gary ^a   Braun, Daniel ^b   Kolterman, Orville ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4;

ACUTE PANCREATITIS; AUTONOMIC NEUROPATHY; BEZOAR; DRUG CONTRAINDICATION; GASTROINTESTINAL DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LETTER; PRIORITY JOURNAL; STOMACH PARESIS;

EID: 42949144525     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997;272:4108-15.
2. Russell FE, Bogert CM. Gila monster: its biology, venom and bite - a review. Toxicon 1981;19:341-59.
3. Christel CM, Denardo DF. Release of exendin-4 is controlled by mechanical action in Gila monsters, Heloderma suspectum. Comp Biochem Physiol A Mol Integr Physiol 2006;143:85-8.
4. Christel CM, Denardo DF, Secor SM. Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum). J Exp Biol 2007;210:3430-9.
5. Byetta. San Diego, CA: Amylin Pharmaceuticals, 2007 (package insert).